BioLineRx Ltd.

BioLineRx Ltd. has established a joint venture with Hemispherian AS to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response for glioblastoma (GBM) and other cancers. GLIX1, which has received FDA IND clearance and Orphan Drug Designation, demonstrated promising preclinical results in GBM models by selectively targeting cancer cells. BioLineRx will manage and fund the development, with plans to initiate a Phase I/IIa clinical trial in Q1 2026, anticipating initial data in H1 2027, addressing a significant unmet medical need in GBM and potentially expanding to other solid tumors, while BioLineRx maintains a cash runway into H1 2027.

Analysis

BioLineRx has strategically repositioned its pipeline by entering a joint venture with Hemispherian AS to develop GLIX1, a first-in-class, oral small molecule for glioblastoma (GBM). The transaction is structured to be capital-efficient, with no upfront payment and BioLineRx's funding commitments directly translating into an increasing equity stake, moving from 40% to a potential maximum of 70%. This de-risks the investment while leveraging BioLineRx's clinical and regulatory expertise. The asset, GLIX1, targets a novel DNA damage response mechanism via the TET2 enzyme, with compelling preclinical data showing complete tumor growth prevention in GBM models, excellent blood-brain barrier penetration, and a favorable safety profile. The IND has been cleared by the FDA, and with Orphan Drug Designation in both the US and EU, the asset is primed for a Phase I/IIa trial commencing in Q1 2026. Initial data from the open-label Phase I portion is a key catalyst, expected in the first half of 2027. The company confirms a cash runway into H1 2027, supported by $28 million in cash and anticipated royalties, which is sufficient to initiate and fund a significant portion of the trial. The initial focus is the $3.8 billion addressable GBM market, with substantial long-term potential from GLIX1's synergy with PARP inhibitors and applicability to other cancers, which the JV can explore.

Key Decisions for Investors

• View this joint venture as a strategically de-risked entry into a high-potential, first-in-class oncology asset, with the key inflection point being the initial open-label Phase I data for GLIX1 in glioblastoma, expected in the first half of 2027.
• Monitor the company's cash runway, which extends into H1 2027, against development costs, as the current resources are stated to cover a 'significant portion' but not necessarily the entirety of the planned Phase I/IIa trial.
• Evaluate the long-term potential beyond the initial glioblastoma indication by tracking any preclinical data on GLIX1's synergy with PARP inhibitors, which could significantly expand the asset's total addressable market.
• Continue to track the nearer-term catalyst from the separate motixafortide program, as the prespecified interim analysis of the Phase IIb pancreatic cancer trial could impact valuation before the GLIX1 program yields clinical data.